==== Front J Pharm Health Care Sci J Pharm Health Care Sci Journal of Pharmaceutical Health Care and Sciences 2055-0294 BioMed Central London 37394446 291 10.1186/s40780-023-00291-0 Short Report Risk factors for thromboembolism during first-line treatment of patients with unresectable advanced or recurrent colorectal cancer: a retrospective short study Takada Ryo takada.ryo.nw@mail.hosp.go.jp Fujiwara Miki Maki Masatoshi Takahashi Yoko Tamura Koji grid.416698.4 Department of Hospital Pharmacy, National Hospital Organization Fukuyama Medical Center, 4-14-17 Okinogami-cho, 720-8520 Fukuyama-city, Hiroshima, Japan 3 7 2023 3 7 2023 2023 9 2227 3 2023 28 5 2023 © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Background While cancer is a risk factor for developing thromboembolism, so is the use of molecularly targeted therapies. This study aimed to determine whether thromboembolism incidence differed between vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibitor use in patients with unresectable advanced or recurrent colorectal cancer, and to compare the risk of thromboembolism caused by cancer and the use of molecular targeted therapy drugs. Main body We retrospectively evaluated patients with unresectable advanced or recurrent colorectal cancer who were treated with a cytotoxic anticancer drug and a VEGF or EGFR inhibitor combination between April 2016 and October 2021. Patients were compared in terms of the regimen administered, thromboembolism occurrence during the first-line treatment period, patient background, and clinical laboratory values. Of the 179 included patients, 12 of 134 (8.9%) in the VEGF-inhibitor group and 8 of 45 (17.8%) in the EGFR-inhibitor group developed thromboembolism, with no significant difference between the groups (P = 0.11). There was no significant difference in time to thromboembolism between patients in the VEGF- inhibitor group and patients in the EGFR-inhibitor group (P = 0.206). The cutoff value determined by a receiver operating characteristic analysis for the occurrence of thromboembolism was one point. Multivariate analysis using the occurrence of thromboembolism as the response variable identified at least one risk factor for thromboembolism (odds ratio = 4.17, P = 0.006, 95% confidence interval = 1.51–11.50). Molecular targeted therapies were not identified as a risk factor. Conclusions Although the small sample size, there was no difference in the incidence of thromboembolism between the two molecular-targeted therapies in first-line treatment of patients with unresectable advanced or recurrent colorectal cancer. Our results suggest that risk factors for thromboembolism may be more strongly influenced by cancer itself than by the use of molecularly targeted therapies. Keywords Colorectal cancer Epidermal growth factor receptor inhibitors Thromboembolism Vascular endothelial growth factor inhibitors issue-copyright-statement© Japanese Society of Pharmaceutical Health Care and Sciences and BioMed Central Ltd. 2023 ==== Body pmcBackground Chemotherapy can improve survival and palliate symptoms of unresectable advanced or recurrent colorectal cancer, and combined administration of a cytotoxic anticancer drug and molecular-targeted therapy, such as vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibitors [1]. Hypertension and proteinuria are typical side effects of VEGF inhibitors, and skin disorders are associated with EGFR inhibitor use. Both drugs are associated with thromboembolism, albeit less frequently. The incidence of thromboembolism is 4–7 times higher in patients with cancer than in those without [2, 3]. Moreover, its annual incidence is 3–5% in patients with colorectal cancer [3], which in itself is a risk factor for thromboembolism development. Regarding drug-related effects, thromboembolism incidence is 11.9% when bevacizumab, a VEGF inhibitor, is used for chemotherapy [4]. Although the effects of EGFR inhibitors, a meta-analysis demonstrated a 1.34-fold increase in thromboembolism incidence in the drug group than that in the control group [5]. However, the incidence of thromboembolism among Japanese patients with colorectal cancer treated with VEGF inhibitors has not been compared with that in patients administered EGFR inhibitors. Additionally, whether cancer itself, and not just the use of molecular-targeted therapies, directly influences the incidence of thromboembolism in patients with colorectal cancer remains unclear. This study aimed to compare the difference in thromboembolism incidence between molecular-targeted agents in patients with unresectable advanced or recurrent colorectal cancer concurrently treated with a cytotoxic anticancer drug and VEGF or EGFR inhibitor, and to determine whether molecular-targeted drug administration or cancer has a greater impact on thromboembolism development. Main text This was a single-center retrospective cohort study that aimed to determine whether thromboembolism incidence differs between VEGF and EGFR inhibitors administered to patients with unresectable advanced or recurrent colorectal cancer, and whether molecular-targeted therapies increase thromboembolism incidence compared with the cancer-bearing condition. We retrospectively analyzed data of 224 patients with unresectable advanced or recurrent colorectal cancer from the Fukuyama Medical Center for Patients, who were treated with concomitant cytotoxic anticancer drug and VEGF or EGFR inhibitor between April 2016 and October 2021. Patients were included only during first-line colorectal cancer treatment. Patients not concomitantly using molecular-targeted agents, those without computed tomography (CT) scan between initiation and completion of first-line treatment, those taking antiplatelet agents or anticoagulants prior to first-line treatment, or those with missing data were excluded. The following parameters were evaluated: sex; age; body weight; body surface area; body mass index (BMI); primary colorectal cancer site; presence or absence of metastases and metastatic sites; type and number of cytotoxic anticancer drugs and molecular-targeted therapies; number of first-line treatments; presence or absence of central venous (CV) port; concomitant heart disease, hypertension, or diabetes mellitus; concomitant use of antiplatelet or anticoagulant medications; concomitant use of hormonal agents or hematopoietic agents; white blood cell (WBC) counts, platelet counts, hemoglobin levels at the start of treatment; and presence of thromboembolism on CT with date and site of occurrence. In addition, the following risk factors for thromboembolism in cancer patients were assigned one point each and summed: WBC count > 11,000 cells/μL, platelet count ≥ 350,000 cells/μL, hemoglobin level < 10 g/dL, and BMI ≥ 25.3 kg/m2 [6, 7]. The Mann–Whitney U test was performed to compare continuous variables between groups and Fisher’s exact probability test for categorical variables. For continuous variables, receiver operating characteristic (ROC) analysis was performed to obtain cutoff values, which were then converted to categorical variables. Multiple logistic regression analysis was performed to examine factors affecting thromboembolism. The occurrence of thromboembolism was the response variable, and VEGF or EGFR inhibitor administration was always included as an explanatory variable. In univariate analysis, event was defined as the onset of thromboembolism or completion of first-line treatment, and time to event occurrence was calculated using the Kaplan–Meier method. The log-rank test was used for comparisons between groups. Statistical significance was set at two-sided P-value of < 0.05. Statistical analyses were performed using EZR version 1.54 (Saitama Medical Center, Jichi Medical University, Saitama, Japan). Of 179 patients, 134 (74.9%) and 45 (25.1%) were in the VEGF- and EGFR-inhibitor groups, respectively. The percentage of patients with a CV port was significantly higher in the EGFR-inhibitor group than in the VEGF-inhibitor group (P < 0.001); however, the other parameters, including the risk factor scores for thromboembolism in cancer patients, did not significantly differ between the groups (Table 1). Thromboembolism incidence was 11.2% (20 patients): 8.9% (8 patients) and 17.8% (12 patients) in the VEGF- and EGFR-inhibitor groups, respectively, showing no significant between-group difference (P = 0.11; Fig. 1A). Similarly, no significant differences were observed for arterial thromboembolism (ATE) and venous thromboembolism (VTE) (Figs. 1B and 1C, respectively). The Kaplan–Meier curve for time to thromboembolism onset in the groups was evaluated, and there was no significant difference between the groups (P = 0.206; Fig. 2). The cutoff value for the number of risk factors for thromboembolism in cancer patients was one point (Table 2). Univariate analysis using thromboembolism occurrence as the response variable revealed that only one or more risk factors for thromboembolism were extracted as influential factors (P = 0.003; Table 3). Similarly, in the multivariate analysis of Model 1 and Model 2, the use of VEGF and EGFR inhibitors was not identified as a risk factor, whereas having at least one risk factor for thromboembolism was identified as a risk factor (P = 0.006, P = 0.006, respectively; Table 3).Table 1 Patient characteristics VEGF-inhibitor group (n = 134) EGFR-inhibitor group (n = 45) P-value Sex (female) 58 (43.3%) 18 (40.0%) 0.731a) Age (year) 69 (33–85) 66 (32–82) 0.345b) Body surface area (m2) 1.570 (1.192–2.010) 1.583 (1.223–1.941) 0.717b) BMI (kg/m2) 21.9 (15.0–36.5) 21.6 (15.9–33.8) 0.958b) Primary rectal tumor 44 (32.8%) 17 (31.1%) 0.588 Number of metastases (n) 1 (1–5) 1 (1–3) 0.589b) Types of molecular-targeted drugs Bevacizumab: 134 (100%) Panitumumab: 40 (88.9%) - Cetuximab: 5 (11.1%) Number of cytotoxic anticancer drugs used in combination (3/2/1) 5/120/9 0/45/0 0.075a) Number of first-line treatments (n) 10.5 (1–62) 9 (1–40) 0.454b) CV port construction, yes (n) 110 (82.1%) 45 (100%)  < 0.001a) Comorbid cardiac disease (n) 2 (1.5%) 3 (6.7%) 0.601a) Comorbid hypertension (n) 35 (26.1%) 16 (35.6%) 0.254a) Comorbid diabetes mellitus (n) 17 (12.7%) 5 (11.1%) 1.000a) Concomitant use of hormonal agents (n) 0 (0.0%) 0 (0.0%) - Concomitant use of hematopoietic agents (n) 0 (0.0%) 0 (0.0%) - WBC count before starting treatment (× 103/μL) 5.55 (2.3–14.4) 5.90 (3.0–11.6) 0.164b) Platelet count before starting treatment (× 103/μL) 230.5 (79–693) 246 (114–454) 0.423b) Hemoglobin level before starting treatment (g/dL) 11.6 (7.9–15.7) 11.6 (6.5–16.4) 0.552b) Number of risk factors (0/1/2/3) 84/41/7/2 25/15/5/0 0.438a) Median number of days from treatment start date to thromboembolism onset date 84.5 (18–200) 101 (7–707) 0.678b) Data are presented as number of cases (%) or median (min–max) values a) Fisher’s exact test, b) Mann–Whitney U test VEGF Vascular endothelial growth factor, EGFR Endothelial growth factor receptor, CV Central venous, BMI Body mass index, WBC White blood cell Fig. 1 Comparison of thromboembolism incidence between molecular-targeted therapies. Fisher's exact probability test was used for all analyses. The horizontal axis shows the rate of events Fig. 2 Time to onset thromboembolism incidence between molecular-targeted therapies Table 2 Cutoff values for the occurrence of thromboembolism for each risk factor in this study Cutoff value AUC 95%CI Sensitivity Specificity BMI (kg/m2) 22.9 0.644 0.515–0.773 0.650 0.642 White blood cell count (× 103/μL) 5.0 0.584 0.454–0.715 0.850 0.403 Platelet count (× 103/μL) 219.0 0.581 0.452–0.710 0.750 0.459 Hemoglobin level (g/dL) 15.2 0.545 0.383–0.706 0.200 0.969 number of risk factor (n) 1 0.666 0.554–0.775 0.648 0.700 BMI Body mass index, 95% CI, 95% confidence interval, AUC Area under the curve Table 3 Factors influencing the occurrence of thromboembolism Number of patients Occurrence of thromboembolism, yes Univariate analysis Multivariate analysis Model 1 Model 2 OR 95% CI P-valuea) OR 95% CI P-value OR 95% CI P-value Sex (female) 76 9 1.12 0.39–3.17 0.815 Age (≧65 years) 110 15 2.01 0.65–7.44 0.228 Primary lesion (Rectum) 61 7 1.05 0.33–3.02 1.000 Metastasis in other organs, yes 131 17 2.23 0.60–12.44 0.287 Comorbid cardiac disease, yes 5 2 5.68 0.45–53.13 0.096 CV port expansion, yes 155 20 inf 0.81–inf 0.080 Use of VEGF inhibitors, yes 134 12 0.46 0.16–1.39 0.110 0.48 0.18–1.31 0.153 Use of EGFR inhibitors, yes 45 8 2.19 0.72–6.34 0.110 2.07 0.76–5.60 0.153 Risk factors for occurrence of thromboembolism≧1 70 14 4.26 1.44–14.30 0.003 4.17 1.51–11.50 0.006 4.17 1.51–11.50 0.006 a)Fisher’s exact test OR Odds ratio, 95% CI, 95% confidence interval, Inf Infinite, CV Central venous, VEGF Vascular endothelial growth factor, EGFR Endothelial growth factor receptor Systemic VEGF inhibition by VEGF inhibitors increases systemic vascular events due to decreased production of nitric oxide (NO), which has vasodilating effects [8] and increased resistance of the vascular endothelium [9]. In addition, EGFR inhibitors suppress VEGF production in tumor cells [10], which results in apoptosis of vascular endothelial cells. Inhibition of VEGF production may indirectly inhibit NO production, thereby disrupting the regenerative capacity of vascular endothelial cells, causing vessel wall defects, and leading to thrombosis [11–17]. Altogether, both VEGF and EGFR inhibitors are risk factors for thromboembolism. The results of this study showed no difference in the incidence of thromboembolism (ATE or VTE) between VEGF and EGFR inhibitors, and no difference in the time to thromboembolism, suggesting that the risk of thromboembolism is similar between molecular-targeted therapies. Recently, it has been reported that panitumumab-based chemotherapy is associated with an increased incidence of serious thromboembolism compared to bevacizumab-based chemotherapy [18]. In this study, the overall incidence of thromboembolism was twice as high in the EGFR inhibitor group, but the possibility of a beta error cannot be ruled out due to the limited number of cases. Khorana et al. [6] reported the following risk factors for thromboembolism in patients with cancer: primary site of cancer type, WBC count > 11,000 cells/μL, platelet count ≥ 350,000 cells/μL, hemoglobin level < 10 g/dL or use of red cell growth factor, and BMI ≥ 35 kg/m2. However, BMI ≥ 35 kg/m2 is based on the obesity standards in Europe and the United States; therefore, this value is not commonly used in Japan. In this study, we considered the following four items as investigable with reference to previous reports among Japanese populations [7]: WBC count > 11,000 cells/μL, platelet count ≥ 350,000 cells/μL, hemoglobin level < 10 g/dL, and BMI ≥ 25.3 kg/m2. The multivariate analysis also showed that more than one risk factor had more influence on thromboembolism than the use of VEGF or EGFR inhibitors. In other words, our results suggest that risk factors for thromboembolism in patients with cancer are more strongly influenced by the cancer itself than by molecular-targeted therapies. However, the fact that it may not be possible to eliminate unknown and unmeasured confounding factors and the small number of events occurring due to the small study size may cause problems with the validity and accuracy of the multivariate analysis. This study has some limitations. First, it was a small, single-center, retrospective analysis. Second, D-dimer levels were not measured in all patients and could not be included. Similarly, a recent study [19] on colorectal cancer reported that the KRAS status is a risk factor for thromboembolism, but we were unable to evaluate it. Third, the effect of molecular-targeted therapy was not compared with that in the non-use group; therefore, the effect could not be accurately determined. Fourth, all patients with thromboembolism had a CV port in the multivariate analysis and were therefore not included in the statistical analysis. However, this is one of the few reports directly comparing the incidence of thromboembolism between VEGF and EGFR inhibitors during first-line treatment of unresectable advanced recurrent colorectal cancer in Japanese patients. Additionally, this is the first report to compare the effect of cancer and molecular-targeted drugs on thromboembolism occurrence, showing that the former may have more influence on thromboembolism development. Conclusions Although the sample size of the study was small, the incidence of thromboembolism during first-line treatment of unresectable advanced or recurrent colorectal cancer did not differ between VEGF and EGFR inhibitor use. Additionally, cancer itself may have a greater impact on thromboembolism incidence than the use of molecular-targeted therapies. Abbreviations VEGF Vascular endothelial growth factor EGFR Epidermal growth factor receptor CT Computed tomography ATE Arterial thromboembolism VTE Venous thromboembolism BMI Body mass index CV Central venous WBC White blood cell ROC Receiver operating characteristic NO Nitric oxide Acknowledgements Not applicable Authors’ contributions All authors meet the ICMJE authorship criteria. RT was responsible for the organization and coordination of the study. RT, MF, and MM were responsible for data analysis. KT was the chief investigator. All authors contributed to the writing of the final manuscript and the management or administration of the study. Funding This research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Availability of data and materials The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate The study protocol was in compliance with the “Ethical Guidelines for Medical Research Involving Human Subjects” and “Appropriate Handling of Personal Information by Medical and Nursing Care Providers” guidelines and was approved by the ethics review committee of the Fukuyama Medical Center (Approval number: ERB202108). Although this study did not obtain direct consent from patients, it disclosed information about conducting the study and guaranteed an opportunity for refusal. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. ==== Refs References 1. Hashiguchi Y Muro K Saito Y Ito Y Ajioka Y Hamaguchi T Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer Int J Clin Oncol 2020 25 1 42 10.1007/s10147-019-01485-z 31203527 2. Prandoni P Lensing A Piccioli AWA Bernardi E Simioni P Girolami B Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 2002 100 3484 3488 10.1182/blood-2002-01-0108 12393647 3. Timp FJ Braekkan SK Versteeg HH Cannegieter SC Epidemiology of cancer-associated venous thrombosis Blood 2013 122 1712 1723 10.1182/blood-2013-04-460121 23908465 4. Nalluri SR Chu D Keresztes R Zhu X Wu S Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis JAMA 2008 300 2277 2285 10.1001/jama.2008.656 19017914 5. Petrelli F Cabiddu M Borgonovo K Barni S Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials Ann Oncol 2012 23 1672 1679 10.1093/annonc/mdr592 22241897 6. Khorana AA Kuderer NM Culakova E Lyman GH Francis CW Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 2008 111 4902 4907 10.1182/blood-2007-10-116327 18216292 7. Nakamura M Fujioka H Yamada N Sakuma M Okada O Nakanishi N Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research Clin Cardiol 2001 24 132 138 10.1002/clc.4960240207 11214743 8. Hood JD Meininger CJ Ziche M Granger HJ VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells Am J Physiol 1998 274 H1054 H1058 9530221 9. Izzedine H Ederhy S Goldwasser F Soria JC Milano G Cohen A Management of hypertension in angiogenesis inhibitor-treated patients Ann Oncol 2009 20 807 815 10.1093/annonc/mdn713 19150949 10. Petit AM Rak J Hung MC Rockwell P Goldstein N Fendly B Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors Am J Pathol 1997 151 1523 1530 9403702 11. Perrotte P Matsumoto T Inoue K Kuniyasu H Eve BY Hicklin DJ Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice Clin Cancer Res 1999 5 257 265 10037173 12. Bruns CJ Solorzano CC Harbison MT Ozawa S Tsan R Fan D Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma Cancer Res 2000 60 2926 2935 10850439 13. Ciardiello F Caputo R Bianco R Damiano V Fontanini G Cuccato S Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor Clin Cancer Res 2001 7 1459 1465 11350918 14. Shen BQ Lee DY Zioncheck TF Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway J Biol Chem 1999 274 33057 33063 10.1074/jbc.274.46.33057 10551875 15. González-Pacheco FR Deudero JJ Castellanos MC Castilla MA Alvarez-Arroyo MV Yague S Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2 Am J Physiol Heart Circ Physiol 2006 291 H1395 H1401 10.1152/ajpheart.01277.2005 16899768 16. Zachary I Gliki G Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family Cardiovasc Res 2001 49 568 581 10.1016/S0008-6363(00)00268-6 11166270 17. Kamba T McDonald DM Mechanisms of adverse effects of anti-VEGF therapy for cancer Br J Cancer 2007 96 1788 1795 10.1038/sj.bjc.6603813 17519900 18. Choi YJ Choi CY Rhie SJ Shin S Safety Assessment on Serious Adverse Events of Targeted Therapeutic Agents Prescribed for RAS Wild-Type Metastatic Colorectal Cancer: Systematic Review and Network Meta-Analysis Int J Environ Res Public Health 2022 19 9196 10.3390/ijerph19159196 35954563 19. Ades S Kumar S Alam M Goodwin A Weckstein D Ashikaga T Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer J Thromb Haemost 2015 13 998 1003 10.1111/jth.12910 25809746